Opinion|Videos|November 12, 2024
Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials
Key Takeaways
- Fezolinetant's approval was based on SKYLIGHT 1, 2, and 4 trials, which were randomized, double-blind, and placebo-controlled.
- The trials focused on women with moderate to severe vasomotor symptoms, evaluating fezolinetant's safety and efficacy.
Panelists discuss the methodologies of the SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 trials that supported the approval of fezolinetant for moderate to severe vasomotor symptoms (VMS) and examine the key safety and efficacy results derived from these studies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (SMITH) The approval of fezolinetant for moderate to severe VMS was based on the
SKYLIGHT 1 ,SKYLIGHT 2 , andSKYLIGHT 4 trials. Briefly describe the methodology of these studies. - (FIFFICK) What were the key safety and efficacy results from the SKYLIGHT studies?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Virtual Reality Intervention Increased Empathy for Patients With MG
2
ICE Presence in Minnesota Health Care Settings Threatens Access to Essential Medical Care
3
Mental Health Distress in Nonmelanoma Skin Cancer Largely Driven by Sociodemographic, Comorbid Factors
4
Strong Patient–Doctor Communication Improves Glaucoma Care: Ariana Levin, MD
5
